ArticleJournal of the Pediatric Orthopaedic Society of North America2025
Fosaprepitant Use as an Antiemetic to Prevent Postoperative Nausea and Vomiting in Pediatric Spinal Fusion Patients May Be Associated With More Rapid Transition to Oral Pain Medication and Reduced Length of Stay.
Article in Journal of the Pediatric Orthopaedic Society of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Significant postoperative nausea and vomiting (PONV) in pediatric patients undergoing posterior spinal fusion is common and limits recovery, prolonging hospital stay. Fosaprepitant is a long-acting antiemetic and works by blocking substance P binding to the neurokinin-1 (NK Methods: This is a retrospective chart review of 173 pediatric patients with idiopathic scoliosis undergoing PSIF. The anesthetic methodology was standardized among both groups. The cohort was divided into two groups according to the use of fosaprepitant intraoperatively (or within four hours postoperatively) or no use. We examined patient characteristics, fosaprepitant dose, incidence of PONV, time to transition from parenteral to oral opioids, and length of hospital stay. Results: 78 (45%) patients received fosaprepitant and 95 (55%) did not. There were no statistically significant differences between groups based on demographics or intraoperative management. No significant difference was found in the incidence of PONV between the groups, but there was a reduction in the number of rescue antiemetics required and a quicker transition from parenteral to oral opioids in the fosaprepitant group. There was also a significantly decreased length of stay. Conclusions: While fosaprepitant did not significantly decrease PONV in pediatric PSIF patients, it was associated with decreased use of additional antiemetics. The patients also demonstrated a more rapid transition to oral from parenteral opioids and a shorter length of hospital stay. A larger study may show a statistically significant reduction in PONV in patients who received fosaprepitant. Future studies are needed to elucidate the optimal dose and timing needed to treat PONV in pediatrics. Key Concepts: (1)Spinal fusion surgery patients are at risk of having significant postoperative nausea and vomiting.(2)Fosaprepitant is an effective agent to treat postoperative nausea and vomiting in adults, but has not been extensively studied in pediatrics for this purpose. Level of Evidence: The level of evidence is a 3 as it is a cohort study looking at the relationship between an exposure and an outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.